Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0032285 (
pneumonia
)
54,520
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Inhibition of the small GTPase RhoA attenuates the development of pulmonary edema and restores positive alveolar fluid clearance in a murine model of Pseudomonas aeruginosa
pneumonia
. Activated protein C (aPC) blocks the development of an unfavorably low ratio of small GTPase Rac1/RhoA activity in lung endothelium through
endothelial protein C receptor
(
EPCR
)/protease-activated receptor-1 (PAR-1)-dependent signaling mechanisms that include transactivating the sphingosine-1-phosphate (S1P) pathway. However, whether aPC's cytoprotective effects can attenuate the development of pulmonary edema and death associated with P. aeruginosa
pneumonia
in mice remains unknown. Thus, we determined whether the normalization of a depressed ratio of activated Rac1/RhoA by aPC would attenuate the P. aeruginosa-mediated increase in protein permeability across lung endothelial and alveolar epithelial barriers. Pretreatment with aPC significantly reduced P. aeruginosa-induced increases in paracellular permeability across pulmonary endothelial cell and alveolar epithelial monolayers via an inhibition of RhoA activation and a promotion of Rac1 activation that required the
EPCR
-PAR-1 and S1P pathways. Furthermore, pretreatment with aPC attenuated the development of pulmonary edema in a murine model of P. aeruginosa
pneumonia
. Finally, a cytoprotective-selective aPC mutant, aPC-5A, which lacks most of aPC's anticoagulant activity, reproduced the protective effect of wild-type aPC by attenuating the development of pulmonary edema and decreasing mortality in a murine model of P. aeruginosa
pneumonia
. Taken together, these results demonstrate a critical role for the cytoprotective activities of aPC in attenuating P. aeruginosa-induced lung vascular permeability and mortality, suggesting that cytoprotective-selective aPC-5A with diminished bleeding risks could attenuate the lung damage caused by P. aeruginosa in critically ill patients.
...
PMID:Cytoprotective-selective activated protein C attenuates Pseudomonas aeruginosa-induced lung injury in mice. 2125 25
Pneumococcal pneumonia is a frequent cause of gram-positive sepsis and has a high mortality. The
endothelial protein C receptor
(
EPCR
) has been implicated in both the activation of protein C (PC) and the anti-inflammatory actions of activated (A)PC. The aim of this study was to determine the role of the
EPCR
in murine pneumococcal
pneumonia
and sepsis. Wild-type (WT),
EPCR
knockout (KO) and Tie2-
EPCR
mice, which overexpress
EPCR
on the endothelium, were infected intranasally (
pneumonia
) or intravenously (sepsis) with viable Streptococcus pneumoniae and euthanised at 24 or 48 hours after initiation of the infection for analyses.
Pneumonia
did not alter constitutive
EPCR
expression on pulmonary endothelium but was associated with an influx of
EPCR
positive neutrophils into lung tissue. In pneumococcal
pneumonia
EPCR
KO mice demonstrated diminished bacterial growth in the lungs and dissemination to spleen and liver, reduced neutrophil recruitment to the lungs and a mitigated inflammatory response. Moreover,
EPCR
KO mice displayed enhanced activation of coagulation in the early phase of disease. Correspondingly, in pneumococcal sepsis
EPCR
KO mice showed reduced bacterial growth in lung and liver and attenuated cytokine release. Conversely,
EPCR
-overexpressing mice displayed higher bacterial outgrowth in lung, blood, spleen and liver in pneumococcal sepsis. In conclusion,
EPCR
impairs antibacterial defense in both pneumococcal
pneumonia
and sepsis, which is associated with an enhanced pro-inflammatory response.
...
PMID:The endothelial protein C receptor impairs the antibacterial response in murine pneumococcal pneumonia and sepsis. 2440 6